Search clinical trials for: GSK2190915 200mg QD (AM)

Total 41 results

GlaxoSmithKline

Completed

Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma

Asthma

Bulgaria, Ukraine, Poland
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

RESIST-2: 2nd-line ART for HIV-2 Infection (RESIST-2)

HIV-2 Infection

Senegal
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients

Acute Myeloid Leukemia

China
GlaxoSmithKline

Completed

GSK2190915 Neutrophilic Asthma Study

Asthma

United Kingdom
GlaxoSmithKline

Completed

A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A

Asthma

United Kingdom
LegoChem Biosciences, Inc

Completed

A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK

Pulmonary Tuberculosis

Korea, Republic of
GlaxoSmithKline

Withdrawn

GSK2190915 Pediatric Study

Asthma
GlaxoSmithKline

Withdrawn

A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval.

Asthma

United Kingdom
Sun Yat-sen University

Unknown

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc (NSCLC EGFR TKI)

Advanced Stage Non Small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

CML, CML-CP,MMR,TKI

China
GlaxoSmithKline

Completed

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

Asthma

United States, Japan, Romania, Ukraine, Bulgaria, Poland
EnnovaBio Australia Pharmaceuticals Pty Ltd

Completed

A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects

Healthy

Australia
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
GlaxoSmithKline

Terminated

GSK2190915 Moderate to Severe Asthma Study

Asthma

United Kingdom, Canada
Rui-hua Xu, MD, PhD

Not yet recruiting

A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD

Advanced Pancreatic Cancer

China
Hutchison Medipharma Limited

Active, not recruiting

HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA)

Warm Antibody Autoimmune Hemolytic Anemia

China
GlaxoSmithKline

Completed

A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin

Asthma

United Kingdom
Corcept Therapeutics

Active, not recruiting

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States, Belgium, Canada, Italy, Spain
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers (ING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Non-Small Cell Lung Cancer、EGFR Sensitive Mutation

China
HK inno.N Corporation

Completed

Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

Erosive Esophagitis

Korea, Republic of
Seoul National University Hospital
IlDong Pharmaceutical Co Ltd

Completed

Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.

Esophageal Disease

Korea, Republic of
Novartis Pharmaceuticals

Active, not recruiting

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.

Chronic Myelogenous Leukemia

Spain, United Kingdom, Germany, Canada, Austria, France, Korea, Republic of, Greece, Singapore, Italy, Argentina, Poland, Vietnam, Malaysia, Oman, Brazil
Sichuan Provincial People's Hospital

Unknown

Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid) (Hybrid)

Stage IV EGFR Mutated NSCL With Brain Metastases

China
Buddhist Tzu Chi General Hospital

Completed

Urinary NGF as A Biomarker for Acute Bacterial Cystitis

Urinary Tract Infection

Taiwan
LG Life Sciences

Completed

Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of
Kuhnil Pharmaceutical Co., Ltd.

Completed

Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled

Dyslipidemias
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer (APPROVE)

Platinum-resistant Recurrent Ovarian Cancer

China
Immunomolecular Therapeutics, Inc.
WCCT Global

Completed

Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes

Type1 Diabetes

United States
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Not yet recruiting

A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Pusan National University Hospital
Yonsei University

Completed

Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA

Hepatitis B, Chronic

Korea, Republic of
Yonsei University
Pusan National University Hospital

Completed

Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA

Hepatitis B, Chronic

Korea, Republic of
Boehringer Ingelheim

Completed

EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA

Cerebrovascular Accident

Germany
University Hospital Ostrava

Completed

REsistance to Aspirin and Clopidogrel in acuTe Myocardial Infarction (REACT-MI)

Acute Myocardial Infarction

Czech Republic
Boehringer Ingelheim

Completed

LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Carcinoma, Non-Small-Cell Lung

Japan
Supernus Pharmaceuticals, Inc.

Completed

Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women (SPN-812)

Healthy Lactating Women

United States
Chengdu University of Traditional Chinese Medicine

Completed

Acupoint Application in Patients With Stable Angina Pectoris (AASAP) (AASAP)

Stable Angina Pectoris

China
Lehigh Center for Clinical Research
Sunovion

Completed

Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder

Insomnia

United States
Fundación Pública Andaluza para la Investigación...
Merck Sharp & Dohme LLC

Unknown

Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study (ROTDIP)

HIV Infections
University of Cape Town
Desmond Tutu HIV Centre; Wits Reproductive Health and HIV Institute

Terminated

Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers (Darifi)

HIV Infections

South Africa
Capital Medical University

Completed

Effectiveness Study of Mirtazapine Combined With Paroxetine in Major Depressive Patients Without Early Improvement

Major Depression

China

3

Subscribe